Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Saskatchewan
$27,000.00
Small protein and peptide-based inhibition of HIV-1 Vif-mediated antagonism of the deoxycytidine deaminase APOBEC3G
EF 2025-26
Résumé
HIV-1 is a viral pathogen for which there is currently no cure. Due to the financial burden and side-effects of lifelong treatments like antiretroviral therapy, more effective HIV-1 therapeutics are highly sought. One target of interest is the viral infectivity factor (Vif) of HIV-1 which is essential for infection of human CD4+ T cells due to its mediation of the degradation of antiviral protein APOBEC3G. While prior research has indicated potential for functional HIV-1 Vif inhibitors, a high-potency therapeutic candidate has yet to be identified. This proposed project aims to test previously developed HIV-1 Vif inhibitors for their ability to prevent Vif-mediated degradation. We hypothesize that developed molecules with the potential for Vif inhibition will allow for a reduction in the degradation of APOBEC3G and that this will allow for the natural function of APOBEC3G to act as an anti-HIV-1 defense. Through standard molecular techniques, a stable cell line will be created which expresses APOBEC3G bound to yellow fluorescent protein. This cell line will be used for quantification of Vif inhibition, with APOBEC3G levels being monitored through fluorescence intensity, either decreasing from Vif-mediated degradation, or increasing due to Vif inhibition. Once established, this proposed method will be used to validate two sets of Vif inhibitors: small Vif-binding proteins previously identified by the Chelico lab, and small peptide traps designed by the Sahtoe lab to target the intrinsically disordered regions of Vif. Should a functional Vif inhibitor be identified, development of preventative therapeutics for HIV-1 infection may be possible. Discovery and clinical implementation of novel Vif inhibitors may reduce both the disease incidence and financial burden of HIV-1.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Saskatchewan, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
572989
Name
Rice William E
Region
Saskatchewan
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Small protein and peptide-based inhibition of HIV-1 Vif-mediated antagonism of the deoxycytidine deaminase APOBEC3G
Programtype2
Studentship Programs
Orgnameinp2
University of Saskatchewan
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Apobec3g; Hiv-1; Intrinsically Disordered Proteins; Mutagenesis; Proteasomal Degradation; Restriction Factors; Stable Cell Lines; Transfection Assays; Vif; Viral Restriction Factors
Abstract
HIV-1 is a viral pathogen for which there is currently no cure. Due to the financial burden and side-effects of lifelong treatments like antiretroviral therapy, more effective HIV-1 therapeutics are highly sought. One target of interest is the viral infectivity factor (Vif) of HIV-1 which is essential for infection of human CD4+ T cells due to its mediation of the degradation of antiviral protein APOBEC3G. While prior research has indicated potential for functional HIV-1 Vif inhibitors, a high-potency therapeutic candidate has yet to be identified. This proposed project aims to test previously developed HIV-1 Vif inhibitors for their ability to prevent Vif-mediated degradation. We hypothesize that developed molecules with the potential for Vif inhibition will allow for a reduction in the degradation of APOBEC3G and that this will allow for the natural function of APOBEC3G to act as an anti-HIV-1 defense. Through standard molecular techniques, a stable cell line will be created which expresses APOBEC3G bound to yellow fluorescent protein. This cell line will be used for quantification of Vif inhibition, with APOBEC3G levels being monitored through fluorescence intensity, either decreasing from Vif-mediated degradation, or increasing due to Vif inhibition. Once established, this proposed method will be used to validate two sets of Vif inhibitors: small Vif-binding proteins previously identified by the Chelico lab, and small peptide traps designed by the Sahtoe lab to target the intrinsically disordered regions of Vif. Should a functional Vif inhibitor be identified, development of preventative therapeutics for HIV-1 infection may be possible. Discovery and clinical implementation of novel Vif inhibitors may reduce both the disease incidence and financial burden of HIV-1.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rice, William E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~